Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Metsera, Inc. MTSR NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
39/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Metsera, Inc. (MTSR) is a Biotechnology company in the Healthcare sector, currently trading at $70.50. It has a SharesGrow Score of 37/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Net income is $209M (loss), growing at -3024.7%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $10M against $287M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 5.34 (strong liquidity). Debt-to-assets is 2.2%. Total assets: $451M.

Analyst outlook: 3 / 4 analysts rate MTSR as buy (75%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 40/100 (Fail), Future 75/100 (Pass), Income ?/100 (Fail).

MTSR SharesGrow Score Overview

49/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 75/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MTSR

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
MTSR: +0%/yr revenue is, -3024.7%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet MTSR: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 5.34 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
MTSR: Gross margin is 0% (+0 pp trend), $7B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
75/100
Analyst outlook: 3 / 4 analysts rate MTSR as buy (75%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range12.3-83.8599
Volume27.87M
Avg Volume (30D)3.5M
Market Cap$7.43B
Beta (1Y)1.70
Share Statistics
EPS (TTM)-2.73
Shares Outstanding$105.05M
IPO Date2025-01-31
Employees93
CEOChristopher Whitten Bernard
Financial Highlights & Ratios
EBITDA$-218.23M
Net Income$-209.13M
Operating Income$-224.83M
Total Cash$352.45M
Total Debt$9.8M
Net Debt$-342.65M
Total Assets$450.99M
Price / Earnings (P/E)-25.8
Analyst Forecast
Rating ConsensusBuy
Analysts Covering4
Buy 75% Hold 25% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS59267L1070

Price Chart

Track all markets on TradingView
MTSR
Metsera, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
12.30 52WK RANGE 83.86

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message